Quantitative Approaches to Structure-Activity Relationships

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 351-369

  Han van de, Waterbeemd ^a   Rose, Sally ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b BioFocus DPI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BIOCHIPS; MOLECULAR GRAPHICS;

COMBINATORIAL CHEMISTRY; PHYSICOCHEMICAL FEATURES; QUANTITATIVE APPROACH; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS (QSAR); QUANTITATIVE STRUCTURE PROPERTY RELATIONSHIPS; STRUCTURE ACTIVITY RELATIONSHIPS; STRUCTURE-PROPERTY CORRELATION; SUBSTITUENT CONSTANTS;

COMPUTATIONAL CHEMISTRY;

EID: 84942872401     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50026-X     Document Type: Chapter

References (77)

1. Smith D.A., Jones B.C., Walker D.K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 1996, 16:243-266.
2. Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies 2001, Wiley-VCH, New York. B. Testa, H. Van de Waterbeemd, G. Folkers, R. Guy (Eds.).
3. Chan O.H., Stewart B.H. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Disc. Today 1996, 1:461-473.
4. Tute M.S. History and objectives of quantitative drug design. Comprehensive Medicinal Chemistry, vol. 4, Quantitative Drug Design 1990, 1-31. Pergamon Press, Weinheim, Zurich. C. Hansch, P.G. Sammes, J.B. Taylor (Eds.).
5. Hansch C. The physicochemical approach to drug design and discovery (QSAR). Drug Dev. Res. 1981, 1:267-309.
6. Hansch C. On the state of QSAR. Drug Inf. J. 1984, 18:115-122.
7. Craig P.N. QSAR - origins and present status: a historical perspective. Drug Inf. J. 1984, 18:123-130.
8. Hansch C. Quantitative structure-activity relationships and the unnamed science. Acc. Chem. Res. 1993, 26:147-153.
9. Hyde R.M., Livingstone D.J. Perspectives in QSAR: computer chemistry and pattern recognition. J. Comput.-Aid. Mol. Des. 1988, 2:145-155.
10. Van de Waterbeemd H. The history of drug research: From Hansch to the present. Quant. Struct.-Act. Relat. 1992, 11:200-204.
11. Martin Y.C. A practioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry. J. Med. Chem. 1981, 24:229-237.
12. Topliss J.G. Some observations on classical QSAR. Perspect. Drug Disc. Des. 1993, 1:253-268.
13. Van de Waterbeemd H. Recent progress in QSAR-technology. Drug Des. Disc. 1993, 9:277-285.
14. Chemometric Methods in Molecular Design 1995, VCH, New York. H. Van de Waterbeemd (Ed.).
15. Testa B., Kier L.B. The concept of molecular structure in structure-activity relationship studies and drug design. Med. Res. Rev. 1991, 11:35-48.
16. Van de Waterbeemd H., Testa B. The parametrization of lipophilicity and other structural properties in drug design. Adv. Drug Res. 1987, 16:85-225.
17. Todeschini R., Consonni V. Methods and Principles in Medicinal Chemistry, vol. 11, Handbook of Molecular Descriptors 2000, Wiley-VCH, Weinheim.
18. El Tayar N., Testa B., Carrupt P.A. Polar intermolecular interactions encoded in partition coefficients: an indirect estimation of hydrogen-bond parameters of polyfunctional solutes. J. Phys. Chem. 1992, 96:1455-1459.
19. Leahy, D.E., Morris, J.J., Taylor, P.J. and Wait, A.R. Membranes and their models: Towards a rational choice of partitioning system. In Silipo, C. and Vittoria, A. (eds). Membranes and their models: Towards a rational choice of partitioning system. In Silipo, C. and Vittoria A. (eds). QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 75-82. Elsevier, Amsterdam.
20. 2 receptor histamine antagonists. J. Med. Chem. 1988, 31:656-671.
21. Van de Waterbeemd H., Kansy M. Hydrogen-bonding capacity and brain penetration. Chimia 1992, 46:299-303.
22. Lombardo F., Shalaeva M.Y., Tupper K.A., Gao F., Abraham M.H. ElogPoct: A tool for lipophilicity determination in drug discovery. J. Med. Chem. 2000, 43:2922-2928.
23. El Tayar N., Marston A., Bechalany A., Hostettmann K., Testa B. Use of centrifugal partition chromatography for assessing partition coefficients in various solvent systems. J. Chromatogr. 1989, 469:91-99.
24. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 1997, 23:3-25.
25. Bevan C.D., Lloyd R.S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 2000, 72:1781-1787.
26. Rose V.S., Rahr E., Hudson B.D. The use of Procrustes analysis to compare different property sets for the characterization of a diverse set of compounds. Quant. Struct.-Act. Relat. 1994, 13:152-158.
27. Rogers D., Hopfinger A.J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comp. Sci. 1994, 34:854-866.
28. Zheng W., Tropsha A. Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbour principle. J. Chem. Inf. Comput. Sci. 2000, 40:185-194.
29. Carlson R., Nordahl A. Exploring organic synthetic experimental procedures. Top. Curr. Chem. 1993, 166:1-64.
30. Topliss J.G. Utilization of operational schemes for analog synthesis in drug design. J. Med. Chem. 1972, 15:1006-1011.
31. Craig P.N. Interdependence between physical parameters and selection of substituent groups for correlation studies. J. Med. Chem. 1971, 14:680-684.
32. Hansch C., Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology 1979, Wiley, Weinheim.
33. Hellberg S., Sjöström M., Skagerberg B., Wold S. Peptide quantitative structure-activity relationships, a multivariate approach. J. Med. Chem. 1987, 30:1127-1135.
34. Van de Waterbeemd H., El Tayar N., Carrupt P.A., Testa B. Pattern recognition study of QSAR substituent descriptors. Comput.-Aid. Mol. Des. 1989, 3:111-132.
35. Skagerberg B., Bonelli D., Clementi S., Cruciani G., Ebert C. Principal properties for aromatic substituents. A multivariate approach for design in QSAR. Quant. Struct.-Act. Relat. 1989, 8:32-38.
36. van de Waterbeemd H., Costantino G., Clementi S., Cruciani G., Valigi R. Methods and Principles in Medicinal Chemistry, vol. 2, Chemometric Methods in Molecular Design 1995, 103-112. VCH, New York. H. Van de Waterbeemd (Ed.).
37. Norinder U., Högberg Th. PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design. Acta Chem. Scand. 1992, 46:363-366.
38. Sadowski J., Kubinyi H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41:3325-3329.
39. Ajay A., Walter W.P., Murko M.A. Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules?. J. Med. Chem. 1998, 41:3314-3324.
40. Van de Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Property-based design: Optimisation of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44:1313-1333.
41. Gorse D., Lahana R. Functional diversity of compound libraries. Curr. Opin. Chem. Biol. 2000, 4:287-294.
42. Gillet V.J., Nicolotti O. Evaluation of reactant-based and product-based approaches to the design of combinatorial libraries. Perspect. Drug Disc. Des. 2000, 20:265-287.
43. Good A.C., Lewis R.A. A new methodology for profiling combinatorial libraries and screening sets: Cleaning up the design process with HARPick. J. Med. Chem. 1997, 40:3926-3936.
44. Martin E., Wong A. Sensitivity analysis and other improvements to tailored combinatorial library design. J. Chem. Inf. Comput. Sci. 2000, 40:215-220.
45. Sheridan R.P., SanFeliciano S.G., Kearsley S.K. Designing targeted libraries with genetic algorithms. J. Mol. Graph. Model. 2000, 18:320-334.
46. Brown R.D., Hassan M., Waldman M. Combinatorial library design for diversity, cost efficiency and drug-like character. J. Mol. Graph. Model. 2000, 18:427-437.
47. Baxter C.A., Murray C.W., Waszkowycz B., Li J., Sykes R.A., Bone R.G.A., Perkins T.D.J., Wylie W. New approach to molecular docking and its application to virtual screening of chemical databases. J. Chem. Inf. Comput. Sci. 2000, 40:254-262.
48. Kubinyi H. Methods and Principles in Medicinal Chemistry, vol. 1, QSAR: Hansch Analysis and Related Approaches 1993, VCH, Weinheim.
49. Grunewald G.L., Dahanukar V.H., Jalluri R.K., Criscione K.R. Synthesis, biochemical evaluation and classical and three-dimensional quantitative structure-activity relationship studies of 7-substituted-1,2,3,4-tetrahydroisoquinolines and their relative affinities toward phenylethanolamine N-methyltransferase and the α2-adrenoreceptor. J. Med. Chem. 1999, 42:118-134.
50. Naito Y., Yamaura Y., Inoue Y., Fukaya C., Yokoyama K., Nakagawa Y., Fujita T. Quantitative structure-activity relationships of 2-[4-(thiazol-2-yl)phenyl]propionic acid derivatives inhibiting cyclooxygenase. Eur. J. Med. Chem. 1992, 27:645-654.
51. Kubinyi H. The Free-Wilson method and its relationship to the extrathermodynamic approach. Comprehensive Medicinal Chemistry, vol. 4, Quantitative Drug Design 1990, 589-643. Pergamon Press, Weinheim. C. Hansch, P.G. Sammes, J.B. Taylor (Eds.).
52. Fleischer R., Frohberg P., Büge A., Nuhn P., Wiese M. QSAR analysis of substituted 2-phenylhydrazonoacetamides acting as inhibitors of 15-lipoxygenase. Quant. Struct.-Act. Relat. 2000, 19:162-172.
53. Cramer R.D. Partial least squares (PLS): its strength and limitations. Perspect. Drug Disc. Des. 1993, 1:269-278.
54. Eriksson L., Johansson E. Multivariate design and modeling in QSAR. Chemom. Int. Lab. Syst. 1996, 34:1-19.
55. Malpass J.A., Salt D.W., Ford M.G., Watcyn E.W., Livingstone D.J. Continuum regression. Methods and Principles in Medicinal Chemistry, vol. 3, Advanced Computer-Assisted Techniques in Drug Discovery 1995, 163-189. VCH, New York. H. van de Waterbeemd (Ed.).
56. Wold S., Eriksson L. Validation tools. Methods and Principles in Medicinal Chemistry, vol. 2, Chemometric Methods in Molecular Design 1995, 309-318. VCH, Weinheim. H. van de Waterbeemd (Ed.).
57. Baroni M., Costantino G., Cruciani G., Riganelli D., Valigi R., Clementi S. Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 1993, 12:9-20.
58. Lotta T., Taskinen J., Bäckström R., Nissinen E. PLS modelling of structure-activity relationships of catechol O-methyl-transferase inhibitors. J. Comput.-Aided Mol. Des. 1992, 6:253-272.
59. Miyashita Y., Ohsako H., Takayama C., Sasaki S. Multivariate structure-activity relationships analysis of fungicidal and herbicidal thiolcarbamates using partial least squares method. Quant. Struct.-Act. Relat. 1992, 11:17-22.
60. Liu Q., Hirono S., Moriguchi I. Quantitative structure-activity relationships for calmodulin inhibitors. Chem. Pharm. Bull. 1990, 38:2184-2189.
61. Rose V.S., Wood J., MacFie H.J.H. Single class discrimination using principal component analysis (SCD-PCA). Quant. Struct.-Act. Relat. 1991, 10:359-368.
62. Manallack D.T., Livingstone D.J. Neural networks in drug discovery: have they lived up to their promise?. Eur. J. Med. Chem. 1999, 34:195-208.
63. King R.D., Hirst J.D., Sternberg M.J.E. New approaches to QSAR: neural networks and machine learning. Perspect. Drug Disc. Des. 1993, 1:279-290.
64. A-Razzak M., Glen R.C. Rule induction applied to the derivation of quantitative structure-activity relationships. Methods and Principles in Medicinal Chemistry, vol. 3, Advanced Computer-Assisted Techniques in Drug Discovery 1995, 319-331. VCH, Weinheim. H. van de Waterbeemd (Ed.).
65. Clarke D.E. Evolutionary Algorithms in Molecular Design 2000, Wiley-VCH, Weinheim.
66. Rose V.S., Croall I.F., MacFie H.J.H. An application of unsupervised neural network methodology (Kohonen topology-preserving mapping) to QSAR analysis. Quant. Struct.-Act. Relat. 1991, 10:6-15.
67. Coats E.A., Cordes H.-P., Kulkarni V.M., Richter M., Schaper K.J., Wiese M., Seydel J.K. Multiple regression and principal component analysis of antibacterial activities of sulfones and sulfonamides in whole cell and cell-free systems of various DDS sensitive and resistant bacterial strains. Quant. Struct.-Act. Relat. 1985, 3:99-109.
68. Hamilton H.W., Ortwine D.F., Worth D.F., Badger E.W., Bristol J.A., Bruns R.F., Haleen S.J., Steffen R.P. Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application. J. Med. Chem. 1985, 28:1071-1079.
69. McFarland J.W., Gans D.J. On the significance of clusters in the graphical display of structure-activity data. J. Med. Chem. 1986, 29:505-514.
70. Rose V.S., Wood J. Generalized cluster significance analysis and stepwise cluster significance analysis with conditional probabilities. Quant. Struct.-Act. Relat. 1998, 17:348-356.
71. Kowalski B.R., Bender C.F. Pattern recognition. II Linear and non-linear methods for displaying chemical data. J. Am. Chem. Soc. 1973, 95:686-693.
72. Domine D., Devillers J., Chastrette M. A nonlinear map of substituent constants for selecting test series and deriving structure-activity relationships. I. Aromatic series. J. Med. Chem. 1994, 37:973-980.
73. Domine D., Devillers J., Chastrette M. A nonlinear map of substituent constants for selecting test series and deriving structure-activity relationships. II. Aliphatic series. J. Med. Chem. 1994, 37:981-987.
74. Anzali S., Barnickel G., Krug M., Sadowski J., Wagener M., Gasteiger J., Polanski J. The comparison of geometric and electronic properties of molecular surfaces by neural networks: Application to the analysis of corticosteroid-binding globulin activity of steroids. J. Comput.-Aid. Mol. Des. 1996, 10:521-534.
75. Lipophilicity in Drug Action and Toxicology 1996, VCH, Weinheim. V. Pliska, B. Testa, H. Van de Waterbeemd (Eds.).
76. Livingstone D. Data Analysis for Chemists 1995, Oxford University Press, Weinheim.
77. Hansch C., Leo A. Fundamentals and Applications in Chemistry and Biology 1995, ACS, Oxford.